68 results about "Glucuronate" patented technology

The invention relates to a traditional Chinese medicine composition which comprises more than 1.09 permillage of ephedrine hydrochloride, more than 0.86 permillage of pseudoephedrine hydrochloride, more than 0.17 permillage of peiminine, more than 0.03 permillage of peimine, more than 0.17 permillage of chrysin-7-O-glucuronide, more than 0.002 permillage of glycyrrhetinic acid, more than 11.87 permillage of amygdalin and more than 0.01 permillage of neotuberostemonine. The oral liquid is prepared from more than 2.16 per mill of glycyrrhizic acid, more than 1.97 per mill of oroxylin A, more than 1.97 per mill of oroxylin B, more than 1.23 per mill of liquiritin, more than 0.59 per mill of apiose liquiritin, more than 0.55 per mill of baicalin, more than 0.23 per mill of chlorogenic acid, more than 0.18 per mill of praeruptorin A, more than 0.15 per mill of wild melanosin, more than 0.14 per mill of methyephedrine hydrochloride, more than 0.13 per mill of isoliquiritin, more than 0.13 per mill of neochlorogenic acid and more than 0.13 per mill of cryptochlorogenic acid. The composition is prepared from more than 0.10% of peimine, more than 0.08% of baicalein, more than 0.05% of praeruptorin B, more than 0.04% of praeruptorin C, more than 0.011% of xanthoxylin and more than 0.0006% of formononetin.

The invention relates to the field of traditional Chinese medicines, and discloses a traditional Chinese medicine composition for treating urolithiasis and preparation and application thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials and monomers in parts by weight: 10 to 30 parts of endothelium corneum gigeriae galli, 10 to 30 parts of rhizoma phragmitis, 10 to 30 parts of poria cocos, 10 to 20 parts of radix angelicae sinensis, 10 to 20 parts of herba cistanche, 10 to 20 parts of herba cepbalanoplosis segeti, 10 to 15 parts of fructus gardeniae, 5 to 10 parts of liquorice root and 1 to 6 parts of gossypotin 8-O-glucuronide. According to the traditional Chinese medicine theory of clearing heat, treating stranguria, dissolving stone and strengthening body resistance, modern pharmacological research is combined, scientific compatibility is carried out through chemical cutting, the synergistic effects of clearing heat, cooling blood, inducing diuresis, treating stranguria, dissolving stone, relieving pain, tonifying kidney and strengthening body resistance are achieved, the preparation process is efficient and controllable, and clinical application is safe and effective.

The present application relates to the technical field of medicine, and provides a kind of haena polysaccharide and its preparation method and application and target endogenous coagulation pathway anticoagulant and / or antithrombotic drug.The haena polysaccharide provided by the present application is fucosylated chondroitin sulfate polysaccharide, the weight average molecular weight is 9-13 million, the molar ratio of glucuronic acid, N-acetylglucosamine and fucose is 1:0.8-1.2:0.5-0.8, and the mass percentage content of sulfate group is 25-40%.The haena polysaccharide provided by the present application can target endogenous coagulation pathway terminal rate-limiting enzyme (iFXase), and has no obvious effect on coagulation factors in other coagulation pathways, realizes the effect of anticoagulation and non-hemorrhage, and can be widely applied in acute and recovery period treatment of ischemic stroke, solves the safety problem of using anticoagulant and antithrombotic drug for clinical ischemic stroke patients, and opens up a new field of research and development of target endogenous coagulation pathway rate-limiting enzyme anticoagulant drug.

The invention discloses a beta-glucuronidase mutant and application thereof, and belongs to the technical field of genetic engineering and protein engineering modification. The beta-glucuronidase mutant disclosed by the invention has the following mutation on the basis of an amino acid sequence as shown in SEQ ID NO.3: T512S or T512A. The catalytic efficiency of the beta-glucuronidase mutant T512S is improved by 13.92 times compared with that of AtGUS (-3t), and the beta-glucuronidase mutant T512S shows remarkable industrial application potential.

The present application relates to the technical field of antibody conjugated drugs, in particular to a drug conjugate with sustained-release property, an antibody conjugated drug and application thereof. The drug conjugate Payload is a payload selected from a drug molecule with cytotoxicity; X is a heteroatom in the payload, selected from O or N; R4 and R5 are independently selected from hydrogen, an alkyl group or other chemical modification groups; R1, R2, R3 and R6 are independently selected from hydrogen, an amino group, a group containing an ether bond, a hydrophilic group, a halogen, an alkyl group or other chemical modification groups; and Glu is a glucuronic acid group. The present application has the advantages of achieving sustained-release effect, increasing stability, avoiding possible non-specific rupture of carbamate bonds in in-vivo circulation, improving the half-life of ADC drugs in blood circulation, reducing toxicity and increasing drug efficacy, and achieving more effective and safe treatment effect due to the sustained-release mechanism which maintains local toxin concentration in a more reasonable killing interval and reduces systemic toxic side effects.

The invention discloses a preparation method and application of a quercetin derivative grafted with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione with a blood sugar reducing function. According to the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound disclosed by the invention, the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is prepared by linking quercetin-3-O-glucuronide with 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione, the structural formula of the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound is shown as a formula (I), and the quercetin-3-O-glucuronide-linked 5-(4-hydroxybenzyl)-2, 4-thiazolidinedione compound prepared by the invention has the function of reducing blood sugar and can be used for preparing medicines for treating diabetes mellitus.

Provided herein are plants, plant parts, a population of plants or plant parts, and plant products (e.g., seed composition, protein composition) comprising reduced activity of a protein-related polypeptide [e.g., stomatal cytokinesis defective 2 (SCD2), SCD2A, SCD2B, response to dehydration 22 (RD22), glucuronidase 3 (GUS3), GUS3A, glycosyl hydrolase family 10 protein B (GH10B), protein phosphatase 2A beta subunit (PP2AB), PPA2BA, PP2ABAB, alpha / beta-hydrolases superfamily protein (ABH), ABHA, ABHB, calmodulin-binding transcription activator protein 2 (CAMTA2), CAMTA2A, CAMTA2B, cinnamyl-alcohol dehydrogenase (CAD1), beta-ketoacyl reductase 1 (KCR1), KCR1A, or KCR1B], and compositions and methods of producing such plants and plant parts. The plants, plant parts, population of plants or plant parts, or plant products can have a genetic mutation that reduces the protein-related polypeptide activity, which can be one located at least partially in a protein-related gene (e.g., CAD1) or its homolog or in its regulatory region, and can have increased protein content and / or white flake protein content.

This invention discloses a recombinant glucuronide C5 epimerase mutant, expression vector, recombinant expression engineered bacteria, and their culture and induction methods, belonging to the field of biotechnology. The recombinant enzyme sequence is formed by fusing a truncated (N29–N617) mutation (V173R–V197K–A239V–N269E) with an N-terminal maltose-binding protein (MBP) tag to a human glucuronide C5 epimerase (C5-epi). The recombinant glucuronide C5 epimerase mutant exhibits higher activity, 2.1 times that of the recombinant wild-type, and greater stability, retaining 72.5% of its activity after 5 days at room temperature. Furthermore, the soluble expression level of this recombinant mutant glucuronide C5 epimerase is increased by 4-fold.

This invention provides the use of β-glucuronidase in the preparation of an antidote for the prevention and / or treatment of zearalenone poisoning, and an antidote for the prevention and / or treatment of zearalenone poisoning, belonging to the field of feed additives. This invention, for the first time from the perspective of in vivo exposure control in animals, proposes a method to reduce the overall ZEN exposure level by inhibiting the activity of intestinal bacterial β-glucuronidase. The technical path is clear and highly operable. This is achieved through in vivo toxicokinetic parameters (AUC, C...). max Changes in (and / or MRT) objectively reflect a reduction in ZEN exposure levels in vivo, and the technical effects are quantifiable and verifiable. The β-glucuronidase inhibitors used in this invention are widely available, particularly suitable for the field of feed additives, and have promising application prospects.

A glucuronidase activator including an active ingredient that is a Levilactobacillus brevis strain I-3141 deposited under accession number CECT 7480.

This invention provides an in vitro cultured bezoar, its preparation method, and its application, belonging to the field of traditional Chinese medicine preparation technology. The preparation method of this invention involves obtaining a bile-resistant, high-β-glucuronidase-active *Escherichia coli* strain through bile gradient acclimation, which is then combined with *Enterococcus faecalis* to form a functional bacterial community. This community is then cultured in vitro through a three-stage process of proliferation, transformation, and crystallization, followed by gradient calcium ion-induced crystallization and vacuum freeze-drying to obtain in vitro cultured bezoar. This invention aims to solve the problems of low conversion efficiency, uneven crystallization, insufficient content of effective components, and unstable product quality in existing technologies. The obtained in vitro cultured bezoar product has significantly higher bilirubin and conjugated bile acid contents than the standards of the *Chinese Pharmacopoeia*, and the process is stable, controllable, and suitable for industrialization.

The invention discloses a stringy stonecrop herb polysaccharide extraction process which comprises the following steps: drying and crushing stringy stonecrop herb, adding water according to a material-liquid ratio of (1: 20)-(1: 60), extracting, concentrating, and carrying out alcohol precipitation to obtain crude polysaccharide; deproteinizing, dialyzing and freeze-drying; carrying out gradient elution and purification to obtain sedum sarmentosum polysaccharide SSBP; an extraction process is optimized through a response surface method, optimal conditions are selected, and the yield of crude polysaccharide reaches 19.06%; according to structural characterization, SSBP is acidic polysaccharide, the molecular weight is 7.484 kDa, 36.12% of uronic acid is contained, monosaccharide is composed of rhamnose, arabinose, galactose, galacturonic acid and glucuronic acid, and the molar ratio of rhamnose to arabinose to galactose to galacturonic acid to glucuronic acid is 12.85: 19.13: 18.98: 35.73: 3.35; an in-vitro activity experiment shows that the SSBP has good antioxidant activity and remarkable anti-inflammatory activity, the release of RAW264.7 macrophage NO induced by LPS and the secretion of IL-6, IL-1beta and TNF-alpha can be inhibited in a dose-dependent manner, and the inhibition rates under the concentration of 1.2 mg / mL respectively reach 74.41%, 92.53%, 95.27% and 95.73%; and a new scheme is provided for deep development of sedum sarmentosum polysaccharide and preparation of anti-inflammatory and anti-oxidation products.

The application discloses a kind of feed additive and its application, it is related to feed additive technical field.The prepared feed additive of the application is by mixing sodium glucuronate, glucomannan, dimethyl cyclodextrin, diatomite and sodium lauryl sulfate, then mixed solution is reacted with calcium chloride crosslinking solution, finally form microspheres type feed additive.Compared with prior art, the prepared feed additive of the application is beneficial to the adsorption of deoxynivalenol and zearalenone, amino acid liquid, lemon yellow and titanium dioxide are mixed, then composite bacteria liquid is added to ferment, by feed additive processing, low-temperature drying can retain the nutrient components and biological activity in raw materials, and the biological fermentation protein raw material with good sensory color is obtained.

The invention provides a novel application of quercetin-3-O-beta-D-glucuronide, belongs to the technical field of medicines, and particularly relates to an application of the quercetin-3-O-beta-D-glucuronide in preparation of anti-aging medicines. According to the invention, quercetin-3-O-beta-D-glucuronide is extracted and separated from lotus leaves, and quercetin-3-O-beta-D-glucuronide can obviously prolong the service life of caenorhabditis elegans and has the effect of delaying senescence, so that quercetin-3-O-beta-D-glucuronide has the potential of delaying senescence, and can be used for preparing a medicine for treating caenorhabditis elegans. The traditional Chinese medicine composition can be applied to preparation of anti-aging medicines and also can be applied to preparation of health-care products for delaying aging.

The application discloses a kind of high-efficiency interception polyvalent anion and cation nanofiltration membrane and its preparation method and application.The method includes the following preparation process:1) preparation concentration is 0.1-2wt% of apigenin class of substance aqueous solution, and concentration is 0.1-0.5wt% of multi-acid chloride organic phase solution;2) make polymer support membrane in aqueous solution 1-5min, remove the surface excess solution, then immerse into oil phase solution, react 1-15min;3) after reaction, remove the surface excess solution, solidify 5-20min under 60-80 DEG C, obtain the nanofiltration membrane.The application is with apigenin, apigenin-7-o-glucuronide and / or isofraxidin as aqueous monomer, and multi-acid chloride is prepared by interfacial polymerization reaction to obtain negative NF membrane, not only maintain the high interception rate to polyvalent anion, and also have very high interception rate to polyvalent cation, can efficiently permeate monovalent ion, and water flux is larger.

This invention discloses a lutein composition for relieving eye fatigue and its preparation method, belonging to the field of functional foods. The process involves: reacting phycocyanin and kelp polyphenols to obtain modified phycocyanin; reacting fucoidan and β-glucuronidase to obtain modified fucose; reacting fish collagen peptides and zinc chloride to obtain collagen peptide-zinc chelate; reacting lutein silica cage complex and modified phycocyanin to obtain a first complex; reacting the first complex and modified fucose to obtain a second complex; reacting the second complex, collagen peptide-zinc chelate, and krill oil to obtain a lutein complex; reacting the second complex, collagen peptide-zinc chelate, and krill oil, then adding trehalose to obtain the lutein complex; and finally mixing the lutein complex with maltodextrin to obtain the lutein composition.

The invention discloses a novel winter jasmine acidic polysaccharide in the technical field of plant extracts. The polysaccharide is expected to become a candidate saccharide medicine for treating pulmonary fibrosis. The polysaccharide is obtained by adopting a water extraction and alcohol precipitation method and separation and purification of an anion exchange column and a gel column. The monosaccharide composition, structural characteristics and related physicochemical properties of the polysaccharide are identified by a chemical or physical method. The neutral sugar content of the polysaccharide is 70-80%, the uronic acid content of the polysaccharide is 50-70%, the protein content of the polysaccharide is 1-7%, and the polysaccharide is mainly composed of mannose, rhamnose, glucuronic acid, glucose, galacturonic acid, galactose and arabinose according to the molar ratio of (1.00-1.50): (10-15): (1.00-5.00): (0.5-1.00): (3-6.00): (15-20.00): (11-17.00). In addition, the polysaccharide has no influence on cell growth activity in vitro and can inhibit fibrosis-related protein expression, which indicates that the polysaccharide possibly has a potential pulmonary fibrosis resisting effect and is expected to become a candidate saccharide drug for treating pulmonary fibrosis.

The present disclosure provides a high-concentration composition of a PD-1 antibody and a method for preparing the same, which comprises pembrolizumab, wherein a portion of the pembrolizumab comprises a glucuronidation modification at the lysine at position 27 of the light chain of the amino acid sequence set forth in SEQ ID NO: 2, and wherein the content of the light chain of the pembrolizumab comprising the glucuronidation modification is less than or equal to 3% based on the percentage of the total content of the light chain of the pembrolizumab in the composition. The present disclosure also provides a pharmaceutical preparation comprising the above-mentioned composition. The present disclosure additionally provides a method for detecting the above-mentioned pembrolizumab comprising the glucuronidation modification and the use thereof in quality inspection or quality control of a product containing pembrolizumab.

A method for screening and efficiently cultivating bezoar strains belongs to the field of bezoar strain screening, and comprises the following steps: step 1, inoculating a culture medium with low-pathogenicity Escherichia coli for culturing, comparing and observing, picking out single colonies with good growth vigor for subculture, and preserving the strains after culture; 2, taking the primarily screened preserved strain, reviving in four regions of an LB solid culture medium by marking lines, selecting a single colony, putting the single colony into a first gradient liquid bile culture medium, culturing, measuring OD600, and if OD600gt is detected, determining that the single colony is not detected; and 0.6, the strain can be placed in a liquid bile culture medium of the next gradient, and the strain which can grow in the three gradients can be inoculated into fresh oxgall for culture. The method has the advantages that the escherichia coli strain with high beta-glucuronidase activity for efficiently cultivating calculus bovis can be obtained, in-vitro cultivation verifies that the escherichia coli strain has bile resistance, calculus bovis analogues can be obtained, and the physicochemical properties of the calculus bovis analogues are similar to those of natural calculus bovis.

The invention relates to a preparation method of high-purity acacetin-7-O-glucuronide, which comprises the following steps of: crushing dry branches and leaves of a verbenaceae plant millettian tree, performing reflux extraction by using a 60-80% methanol solution, combining extracting solutions, and concentrating to obtain an extract; carrying out gel column chromatography on the extract, carrying out gradient elution by using a methanol-water system, detecting by using thin-layer chromatography (TLC), collecting eluent containing acacetin-7-O-glucuronide, merging, and concentrating under reduced pressure to obtain crude fraction of acacetin-7-O-glucuronide. And separating and purifying by using preparative high performance liquid chromatography (PHPLC), and detecting each part of collected eluent by using high performance liquid chromatography (HPLC) to obtain the acacetin-7-O-glucuronide component with the purity of more than 98%. And carrying out TLC and HPLC purity detection and content determination on the obtained product, and establishing a quality control method. The process is simple and reasonable in design, high in separation speed, short in production period, high in product purity, controllable in quality and suitable for industrial production.

The invention belongs to the technical field of biological medicines, and relates to a high-affinity antigen of an autoimmune disease antibody as well as a synthesis method and application of the high-affinity antigen. According to the method, a one-pot multi-enzyme system is utilized, a compound 1 is taken as a starting receptor, and N-acetylglucosamine is connected to a non-reducing terminal of the compound 1 through a beta1, 3-glucosidic bond to generate a trisaccharide compound; the method comprises the following steps: connecting galactose to a non-reducing terminal of a trisaccharide compound through a beta 1, 3-glucosidic bond by using a one-pot multi-enzyme system to generate a tetrasaccharide compound: connecting glucuronic acid to a non-reducing terminal of the tetrasaccharide compound through a beta 1, 3-glucosidic bond by using the one-pot multi-enzyme system to generate a pentasaccharide compound; a one-pot multi-enzyme system is utilized to obtain a sulfuric acid group from PAPS, and the sulfuric acid group is transferred to a C3 site of glucuronic acid at the tail end of a pentasaccharide compound to form an HNK-1 epitope. According to the method disclosed by the invention, the preparation of the HNK-1 can be realized without protection and deprotection strategies. And the prepared I-type HNK-1 antigen has relatively high affinity to an anti-MAG antibody.

The invention discloses a method for synthesizing a pevitide key intermediate, and relates to the technical field of medicine synthesis. The specific preparation method comprises the following steps: firstly, reacting 2, 3, 4, 6-tetraacetoxy-alpha-D-glucopyranose bromide with 18-hydroxy tert-butyl octadecanoate under the action of a catalyst to generate a glycoside intermediate, and carrying out alkaline hydrolysis on the glycoside intermediate to remove an acetyl protecting group, so as to obtain the 2, 3, 4, 6-tetraacetoxy-alpha-D-glucopyranose. And finally, carrying out oxidation reaction and purification to obtain a target product 18-([beta-D-glucuronic acid-1-yl] oxy) tert-butyl octadecanoate, namely the pevitide key intermediate. According to the preparation method disclosed by the invention, the pevitide key intermediate with relatively high yield and purity can be finally obtained, and the preparation method is simple to operate and has a good application prospect.

The present invention relates to a Lactiplantibacillus plantarum) LM1001 (Accession No. KCCM13370P) strain, and a composition for promoting proteolysis, comprising, as an active ingredient, one or more of a culture, lysate, or extract of the strain. The Lactiplantibacillus plantarum LM1001 strain according to the present invention has excellent proteolytic activity, can produce branched-chain amino acids (glutamic acid, tyrosine, alanine, and lysine) that can help produce muscle and prevent muscle loss by degrading whey protein, has excellent β-galactosidase or α-galactosidase activity, and does not have β-glucuronidase activity, and thus the present invention has the effect of ameliorating indigestion, diarrhea, abdominal bloating, and the like due to protein intake.

The application discloses a novel brown algae polysaccharide SARP for promoting healing of diabetic ulcers and a preparation and application thereof. A novel SARP is obtained through Sephacryl S-300 / HR gel column separation and purification, and the molecular weight of the SARP is about 45.4 kDa, which is composed of mannuronic acid (76.56%), guluronic acid (18.89%) and a small amount of glucuronic acid (4.55%). Compared with alginate separated from other brown algae, the SARP has a higher content of mannuronic acid. The SARP shows a better in-vitro antioxidant capacity, and can obviously reverse the cell damage of HUVECs caused by H2O2 and high sugar in the HUVECs. In addition, the SARP can promote the migration and tubular formation of the HUVECs. In-vivo experiments further show that the SARP can promote the healing of diabetic ulcer in rats, and can reduce the oxidative stress, inflammation level and lipid disorder in the rats. The SARP has a simple purification route, can be prepared in a large amount, and is a very promising novel drug for treating diabetic foot ulcers.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, allo-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

There is provided a compound of formula (I) wherein the conjugate is a group capable of binding a BA and joining the BA to the remainder of the compound, the cleavable quantum comprises at least one site capable of being cleaved by a beta-glucuronidase, the spacer provides a distance between the conjugate and a payload, the payload being a cytotoxic agent, such as MMAE, and BA is a binding agent selected from the group consisting of a humanized antibody, a monoclonal antibody, a chimeric antibody or a human antibody or an antigen-binding fragment thereof. (I)

This invention relates to the field of pharmaceutical and chemical intermediates technology, and discloses a novel class of substituted phenylethyl-O-β-D-glucuronide compounds. These compounds are generated using substituted phenylethanol as a substrate and 1-fluoro-D-glucuronic acid as a glycosyl donor, catalyzed by β-glucuronyltransferase derived from *E. coli*. The process yield can reach over 95%, and the reaction conditions are mild and environmentally friendly. Substituted phenylethyl-O-β-D-glucuronide can be efficiently used for the determination of β-glucuronidase activity, and its applications are wide-ranging and reliable. The product can meet the needs of pharmaceutical, food, and other fields for β-glucuronidase activity control. It can be used for enzyme activity detection in the auxiliary diagnosis of clinical diseases, and also for enzyme quality control in fruit juice clarification processes in the food industry, drug precursor activation, and glycan structure analysis in the biopharmaceutical field. The product structure has been verified to be accurate by mass spectrometry and 1H NMR spectroscopy, and enzymatic hydrolysis experiments have confirmed its reliable application.

The invention discloses an inositol oxygenase mutant and application of the inositol oxygenase mutant in preparation of D-glucuronic acid, and belongs to the technical field of genetic engineering. The inositol oxygenase mutant is obtained by mutating P into G from the 116th amino acid of an amino acid sequence as shown in SEQ ID NO.1. The 116th amino acid of wild type inositol oxygenase is mutated, and the enzyme activity of the obtained inositol oxygenase mutant P116G is remarkably improved, so that the yield of D-glucuronic acid is further improved when the D-glucuronic acid is prepared.

The invention provides application of lycium ruthenicum polysaccharide extract in preparation of a medicine for treating peripheral neuropathy, and belongs to the technical field of lycium ruthenicum polysaccharide. The lycium ruthenicum polysaccharide disclosed by the invention comprises galacturonic acid, galactose, glucose, arabinose, rhamnose, xylose, mannose, glucuronic acid and glucosamine, wherein the molar ratio of the galacturonic acid to the galactose to the glucose to the arabinose to the rhamnose to the xylose to the mannose to the glucuronic acid to the glucosamine is 0.309 to 0.164 to 0.156 to 0.141 to 0.107 to 0.074 to 0.035 to 0.009 to 0.007. The lycium ruthenicum polysaccharide has good antioxidant activity, relieves hematopoietic toxicity and liver and kidney injury induced by OXA, resists mechanical hyperalgesia and cold stimulation, enhances an antioxidant defense mechanism to improve injury caused by oxidative stress, and improves neuromorphological characteristics of oxaliplatin-induced dorsal root ganglion.

Disclosed in the present invention is a composition for preventing, alleviating or treating periodontitis, the composition containing, as an active ingredient, a potentilla chinensis extract, apigenin-7-O-β-glucuronide, or a sitologically acceptable salt thereof. The present invention inhibits the mRNA expression of COX-2, IL-6, and MMP-3 and reduces the CEJ-ABC distance, thus suppressing inflammation, protecting the periodontium, and mitigating bone loss. Therefore, the present invention has the effects of preventing, alleviating or treating periodontitis.